Federal Court in Canada Upholds Pfizer's Norvasc Patent; Decision Prevents Launch...

* Reuters is not responsible for the content in this press release.

Thu Apr 17, 2008 4:24pm EDT 

Federal Court in Canada Upholds Pfizer's Norvasc Patent; Decision Prevents Launch of Generic Amlodipine Besylate Product by Pharmascience until 2010

NEW YORK--(Business Wire)--
Pfizer Inc said today that the Canadian Federal Court has upheld a
Pfizer patent covering amlodipine besylate, the active ingredient in
Norvasc. The court issued an order prohibiting regulatory approval of
Pharmascience's proposed product in Canada until Pfizer's amlodipine
besylate patent - Canadian Patent No. 1,321,393 - expires in August
2010. Pharmascience may appeal the decision to the Federal Court of
Appeal of Canada.

   The company noted that legal challenges to this patent in Canada
by other generic manufacturers are still pending.

Pfizer Inc
Chris Loder, 212-733-7897

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.